NHS National Generic Pharmaceuticals Transition 2021_2 - Pemetrexed Solution for Infusion - LSNE

Tender description

NHS National Pharmaceuticals Transition 2021_2 - Pemetrexed solution for infusion LSNE region.Offer reference number: CM/PHG/21/5639/00Period of framework agreement: The total maximum duration of the framework agreement to be no more than 38 months (19 months plus options to extend (at the Authority's sole discretion) for up to a further 19 months)FIND A TENDER (FTS) Reference number: 2021/S 000-008845Potential periods of call-offs under the framework agreement: 24/06/2021 to 31/01/2023 (19 months) LSNE region. Lot 1: NHS National Pharmaceuticals Transition 2021_2 - Pemetrexed solution for infusion LSNE regionOffer reference number: CM/PHG/21/5639/00Period of framework agreement: The total maximum duration of the framework agreement to be no more than 38 months (19 months plus options to extend (at the Authority's sole discretion) for up to a further 19 months)Potential periods of call-offs under the framework agreement:24/06/2021 to 31/01/2023 (19 months) LSNE region. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Lot 1: NHS National Pharmaceuticals Transition 2021_2 - Pemetrexed solution for infusion LSNE regionOffer reference number: CM/PHG/21/5639/00Period of framework agreement: The total maximum duration of the framework agreement to be no more than 38 months (19 months plus options to extend (at the Authority's sole discretion) for up to a further 19 months)Potential periods of call-offs under the framework agreement:24/06/2021 to 31/01/2023 (19 months) LSNE region. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents